Navigation Links
Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
Date:3/10/2010

SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel.

The live presentation takes place Tuesday, March 16, 2010 at 12:30 p.m. Eastern Time (ET)/9:30 a.m. Pacific Time (PT).  The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.

Back to top

RELATED LINKS
http://www.neurocrine.com

'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
3. Neurocrine Biosciences Amends Corporate Headquarters Lease
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences Secures Committed Equity Financing Facility
6. Neurocrine Biosciences Reports Second Quarter 2009 Results
7. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
9. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
10. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
11. Neurocrine Biosciences Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- According to the new market ... Instruments, Automated Cell Expansion System), Cells Types (Human, ... Cancer, and Cell-Based Research), End-users (Biopharmaceutical and Biotechnology ... Trends, Growth, Share, Size and Forecast to 2022", ... expansion market is expected to reach USD 18.74 ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016 NxGen MDx announced today ... bringing the test in house, we,ve been able to improve customer service ... for patients," says Alan Mack , CEO of NxGen MDx. ... , , ... test volume has led to more job opportunities at the Grand Rapid ...
(Date:12/5/2016)... -- The U.S. Biotechnology industry is the ... revenue and some $890 billion of total market value. In ... and this figure is expected to exceed $220 billion ... four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ACOR ...
(Date:12/4/2016)...  In five studies being presented today during the ... Exposition in San Diego , researchers ... delivery of life-saving treatments to patients with a variety ... carry therapies directly to the sites in the body ... substantial advantage over traditional, systemic methods. The studies highlight ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):